These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15970671

  • 1. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
    Czibere A, Prall WC, Zerbini LF, Grall F, Craigie EC, Ulrich SD, Giagounidis AA, Haas R, Libermann TA, Aivado M.
    Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
    [Abstract] [Full Text] [Related]

  • 2. Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
    Czibere A, Prall WC, Zerbini LF, Jäger M, Kobbe G, Knipp S, Libermann TA, Haas R, Aivado M.
    Br J Haematol; 2006 Nov; 135(3):355-7. PubMed ID: 16978222
    [Abstract] [Full Text] [Related]

  • 3. The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway.
    Singh R, Cadeddu RP, Fröbel J, Wilk CM, Bruns I, Zerbini LF, Prenzel T, Hartwig S, Brünnert D, Schroeder T, Lehr S, Haas R, Czibere A.
    Apoptosis; 2011 Sep; 16(9):889-901. PubMed ID: 21739277
    [Abstract] [Full Text] [Related]

  • 4. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
    De Witte T, Muus P, De Pauw B, Haanen C.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
    [Abstract] [Full Text] [Related]

  • 5. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
    Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.
    Leukemia; 2016 Jan; 30(1):112-23. PubMed ID: 26153654
    [Abstract] [Full Text] [Related]

  • 6. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, Zhou AX, Toyoda H, Hirano T.
    Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
    [Abstract] [Full Text] [Related]

  • 7. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    De Witte T, Muus P, De Pauw B, Haanen C.
    Cancer; 1990 Sep 01; 66(5):831-7. PubMed ID: 2386911
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S.
    Eur J Haematol; 2020 Feb 01; 104(2):125-137. PubMed ID: 31758597
    [Abstract] [Full Text] [Related]

  • 10. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H, Tsushima Y, Nagai K, Yagihashi S.
    Acta Haematol; 2000 Feb 01; 102(3):115-23. PubMed ID: 10692673
    [Abstract] [Full Text] [Related]

  • 11. Apparent expansion of CD34+ cells during the evolution of myelodysplastic syndromes to acute myeloid leukemia.
    Span LF, Dar SE, Shetty V, Mundle SD, Broady-Robinson L, Alvi S, Raymakers RA, de Witte T, Raza A.
    Leukemia; 1998 Nov 01; 12(11):1685-95. PubMed ID: 9823942
    [Abstract] [Full Text] [Related]

  • 12. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM.
    J Clin Oncol; 2015 Nov 01; 33(31):3641-9. PubMed ID: 26304885
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Liberante FG, Pouryahya T, McMullin MF, Zhang SD, Mills KI.
    Oncotarget; 2016 Feb 09; 7(6):6609-19. PubMed ID: 26735888
    [Abstract] [Full Text] [Related]

  • 15. Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.
    Xiong XX, Liu JM, Qiu XY, Pan F, Yu SB, Chen XQ.
    Acta Pharmacol Sin; 2015 Mar 09; 36(3):362-74. PubMed ID: 25619389
    [Abstract] [Full Text] [Related]

  • 16. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Chen X, Othus M, Wood BL, Walter RB, Becker PS, Percival ME, Abkowitz JL, Appelbaum FR, Estey EH.
    Leuk Lymphoma; 2021 May 09; 62(5):1226-1233. PubMed ID: 33345655
    [Abstract] [Full Text] [Related]

  • 17. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
    Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, Aguiar E, Bergua J, López-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodríguez-Medina C, López-Pavía M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodríguez-Gutiérrez JI, Benavente C, Costilla-Barriga L, García-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, García-Belmonte D, Herráez MM, Vasconcelos Esteves G, Gómez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MÁ, Montesinos P.
    Blood Adv; 2022 Feb 22; 6(4):1278-1295. PubMed ID: 34794172
    [Abstract] [Full Text] [Related]

  • 18. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
    Lim JT, Joe AK, Suzui M, Shimizu M, Masuda M, Weinstein IB.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3478-84. PubMed ID: 16740773
    [Abstract] [Full Text] [Related]

  • 19. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C, Chi J, Wang L.
    Ann Med; 2015 May 01; 47(3):209-17. PubMed ID: 25861829
    [Abstract] [Full Text] [Related]

  • 20. The incidence, risk factors, and survival of acute myeloid leukemia secondary to myelodysplastic syndrome: A population-based study.
    Ye X, Chen D, Zheng Y, Wu C, Zhu X, Huang J.
    Hematol Oncol; 2019 Oct 01; 37(4):438-446. PubMed ID: 31378958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.